Conversations in Drug Development
In this episode, Dr Katherine Bowen and Dr Julie Warner delve deep into the ever-evolving world of oncology drug development and the regulatory landscape in the US and EU. Join us in this conversation, as we cover the key shifts in the field over the past few decades, regulatory challenges, FDA initiatives and future developments in oncology drug development, including the impact of AI, machine learning, and CRISPR technologies.
To discuss this episode of Conversations in Drug Development with a member of the team, visit www.boydconsultants.com